Alira Health

Alira Health

Risk and Mitigation Actions for Clinical Trials During COVID-19 Pandemic (RiMiCOPa)

Uncategorized
Category:
Published on:
January 10, 2021

COVID-19 continues to affect clinical trials, both directly and indirectly, across the world.  Each step, from protocol design to results disclosure, needs to be revised to assess COVID-19 impact, evaluate the potential risks, and establish a mitigation plan. In November 2020, the National Center for Biotechnology Information published our recommendations, “Risk and mitigation actions for clinical trials during COVID-19 pandemic (RiMiCOPa),” written by Alira Health’s Antonella Bacchieri, Senior Consultant Statistician, and Paolo Morelli, Executive Vice President, Biometrics, in collaboration with Andrea Rossi, Consultant in Medical Writing, Communications and Scientific Affairs. 

The RiMiCOPa document, based on EMA and FDA guidelines, provides advice on evaluating how the different aspects of clinical trials should be handled to mitigate the impact of the COVID-19 pandemic on data management, statistics, and medical writing activities, maintaining the required quality standards.

Related news

Events May 14, 2024
PSI 2024 Conference
Biometrics Biostatistics Data Science
Reports May 7, 2024
Calculator for Simon’s Two-Stage Design and Its Modifications
Our statisticians developed this calculator for a rapid evaluation of the trial. You can get an early futility assessment and modify the design while the trial is still going on. The(...)
Biometrics Biostatistics
Articles June 6, 2023
Content of Integrated Summaries of Efficacy and Safety (ISE/ISS): A Blog Series
Content of Integrated Summaries of Efficacy and Safety (ISE/ISS) blogs outline what elements are required for successful FDA submissions.
Biometrics ISE/ISS
Articles May 30, 2023
Specific Requirements for Integrated Summaries of Efficacy and Safety in FDA Submissions
This article in our Content of Integrated Summaries of Efficacy and Safety series focuses on specific requirements for FDA submissions.
Biometrics ISE/ISS
Articles May 19, 2023
Content of the Integrated Summaries of Efficacy and Safety
This article in our Content of ISE/ISS series focuses on what elements are required in the ISE/ISS to ensure a successful submission.
Biometrics ISE/ISS
Articles May 11, 2023
Introduction to Integrated Summaries of Efficacy and Safety
This article in our ISE ISS series focuses on the structure of the common technical document (CTD) and the objectives of the ISE/ISS.
Biometrics ISE/ISS
Events November 4, 2022
PHUSE EU 2022
We are pleased to announce that we will be joining as sponsors and delegates PHUSE EU, an event that brings together the PHUSE global community to collaborate on hot topics guiding(...)
Biometrics Biostatistics
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.